SUNNYVALE, Calif. and NEWTON, Mass. — December 10, 2025 — Leads & Copy — 4D Path, AMD, and Oracle are collaborating to advance predictive oncology and accelerate clinical trials.
4D Path, a company focused on personalizing cancer care through therapy response prediction, will utilize AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI) to enhance its QPOR™ platform. The QPOR™ platform, a physics-informed, AI-driven software engine, will convert biopsy images into interpretable biomarkers of tumor and immune response, aiming to do so faster and at a lower cost.
QPOR’s native CPU operation ensures trial-level reproducibility, cost efficiency, and scalability. The automated, end-to-end solution ingests whole-slide images to produce biomarker outputs, facilitating consistent deployment across clinical sites.
Clinicians, CROs, and sponsors can leverage the platform’s regulatory-friendly insights for quicker clinical trial execution and personalized cancer care. QPOR has demonstrated readiness for real-world oncology applications, validated through blinded retrospective studies and ongoing prospective clinical trials.
According to Tathagata Dasgupta, founder, president and CTO of 4D Path, the company’s mission is to make predictive oncology explainable and scalable. He stated that using AMD EPYC on OCI allows the delivery of reproducible, trial-ready biomarkers from routine pathology slides, which meets the expectations of regulators, clinicians, and payers.
Tony Nunes, senior manager, Healthcare and Life Sciences at AMD, noted that 4D Path exemplifies how cutting-edge science utilizes AMD EPYC processors to bring high-throughput, AI-powered imaging analytics to healthcare efficiently.
Chris Gandolfo, executive vice president at Oracle Cloud Infrastructure and AI, stated that OCI provides the trusted foundation for advancing oncology analytics, delivering insights at scale with the security and compliance healthcare partners expect.
4D Path’s patented Q-Plasia OncoReader (QPOR™) platform is designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy. This facilitates more effective, personalized therapies for patients.
The company envisions a future where individuals impacted by cancer receive quick, accurate diagnoses and personalized treatment plans for longer, healthier lives.
PR Contact Jordan Bouclin / Jill Anderson
SVM PR & Marketing Communications
Jordan.bouclin@svmpr.com / Jill.anderson@svmpr.com
(401) 490-9700
Source: 4D Path
